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Abstract: The most important function of the skin is to form a barrier between the body and 
the external environment. The epidermal barrier prevents transepidermal water loss from the 
skin, but also serves as a barrier to the entry of harmful environmental allergic, toxic or 
infectious substances. Inherited defects in the genes encoding the components of the epider-
mal barrier result in the development of rare genetic disorders, whereas polymorphisms in 
these genes together with environmental factors cause frequent inflammatory skin diseases, 
such as atopic dermatitis. In this review, components of the skin-barrier function will be 
reviewed with special emphasis on how the altered epidermal barrier might be repaired. The 
different strategies to increase the transdermal penetration of drugs is also discussed.  
Keywords: Cutaneous barrier, barrier development, barrier impairment, barrier repair. 
INTRODUCTION 
 The human skin forms a complex barrier between our bodies 
and the external environment [1,2]. It has been known for a long 
time that epidermal keratinocytes, making up the outermost ana-
tomical structure the epidermis, form an important physical barrier. 
These cells are the bricks in the outer wall of our bodies; they are 
very strongly attached to one another by specialized organelles 
called tight junctions, and the extracellular space between them is 
very small [3]. This is an important feature of this tissue, as it pre-
vents the loss of water and other important chemicals. In addition, 
when this layer is intact, it makes it very difficult for environmental 
molecules and other harmful invaders (e.g., different microbes) to 
enter our bodies through this strong mechanical boundary.  
 The epidermis is also a stratified squamous epithelium in which 
continuously proliferating basal cells in the stratum basale give rise 
to new keratinocytes that gradually move to the upper epidermal 
layers (stratum granulosum, spinosum and lucidum). During these 
events the cells undergo natural differentiation processes. The 
keratinocytes become flattened, and their cytoplasm is gradually 
filled with keratin filaments, which are deposited into a matrix 
composed of mostly filaggrin and its breakdown products, to the 
point of the death of cells. In the resulting specialized tissue called 
stratum corneum (SC), dead keratinocytes (corneocytes) are held 
together by a ‘mortar’ composed of a lipid-enriched extracellular 
matrix containing ceramides (50%), cholesterol (30–35%) and free 
fatty acids (10–15%) [2,4-6]. These lipids are synthesized and re-
leased from lamellar bodies at the stratum granulosum – SC-
interface, and their final processing is done by hydrolytic enzymes 
also released in parallel with the lipid precursors [7]. Together with 
the corneocytes, they form a dry, completely insoluble and nearly 
impermeable physical structure. 
 Apart from the formation of the mechanical or physical barrier, 
another level of protection is the special acidic environment 
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(chemical barrier) established in the first few weeks after birth and 
maintained on our skins throughout life [8]. This acidic ‘mantle’ is 
important for permeability barrier formation and also for antimicro-
bial defense. It is a result of various acidic components of eccrine 
and sebaceous secretions, proton pumps, and breakdown products 
of processed lamellar body lipids [9].  
 Finally, our skin cells are in close connection with a specialized 
microbial flora, called the cutaneous microflora or microbiota [10]. 
Together with the skin cells, they form an immunological barrier, 
provide efficient protection from harmful pathogenic microorgan-
isms and also, when in a balanced state, help to maintain the integ-
rity and the healthy homeostasis of our bodies. Even though their 
role has long been suggested, the exact cellular and molecular 
mechanism contributing to these functions is just being uncovered. 
In this paper, we summarize what is currently known on this topic. 
 The cutaneous barrier is very complex, highly organized and 
strictly regulated. Its structure and function is, in part, genetically 
programmed. This is proven by the existence of inherited factors, 
mutations and polymorphisms that affect the development, as well 
as the structure and thereby also the function of our skins, often 
leading to the pathogenesis of various cutaneous disorders. 
GENETICS OF THE EPIDERMAL BARRIER AND ASSO-
CIATED DISEASES 
 Large-scale transcriptome profiling of granular keratinocytes 
revealed genes (n=330) that are involved in the formation of the 
epidermal barrier and in the maintenance of its physiological func-
tions [11]. Among the identified genes are several that are impli-
cated in the transformation of granular keratinocytes into corneo-
cytes, in lipid metabolism and transport or in composition and deg-
radation of cell–cell junctions (summarized in Table 1) [11]. Cor-
neocytes contain abundant keratin: approximately 60% of their dry 
weight is keratin proteins [12,13]. In epidermal barrier formation, 
proteins encoded by the keratin (KRT) 1, 2 and 10 genes are impli-
cated with pivotal roles [13]. The cornified envelopes of the cor-
neocytes contain a large amount of filaggrins, which are associated 
with keratin intermediate filaments and packed into bundles 
[14,15]. The keratin-filaggrin bundles contribute to the insolubility 
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Table 1. Genes involved in the development of the epidermal barrier and their associated diseases.  
 Genes involved in the formation of 
the epidermal barrier 
Associated diseases References 
KRT 1 Epidermolytic hyperkeratosis, palmoplantar keratodermas [12, 13, 50] 
KRT2 Epidermolytic hyperkeratosis [12, 13, 52] 
KRT10 Epidermolytic hyperkeratosis, ichthyosis with confetti [12, 13, 52,53] 
FLG Ichthyosis vulgaris, atopic dermatitis [14,15, 16, 17,48,49] 
LOR Loricrin keratoderma [18] 
TGM1 Autosomal recessive congenital ichthyosis [17,44,45,47] 
POMP Keratosis linearis with ichthyosis congenita and sclerosing keratoderma [19] 
ERCC2 Trichothiodystrophy [20,21] 
ERCC3 Trichothiodystrophy [20,21] 
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C7ORF11 Trichothiodystrophy [20,21] 
FALDH Sjögren-Larsson syndrome [22] 
PHYH Refsum syndrome [23,24] 
ALOX12B Autosomal recessive congenital ichthyosis [25] 
ALOXE3 Autosomal recessive congenital ichthyosis [25] 
CYP4F22 Autosomal recessive congenital ichthyosis [26,27] 
NIPAL4 Autosomal recessive congenital ichthyosis [26,27] 
LIPN Autosomal recessive congenital ichthyosis [26,27] 
STS X-linked ichthyosis [28,29,30] 
EBP Conradi-Hünermann-Happle syndrome, MEND syndrome [28,29,30,54] 
MBTPS2 Ichthyosis follicularis-alopecia-photophobia syndrome, keratosis follicu-
laris spinulosa decalvans, olmsted syndrome 
[28,29,30] 
SLC27A4 Ichthyosis prematurity syndrome [31,32] 
ABCA12 Autosomal recessive congenital ichthyosis [31,32] 
AP1S1 MEDNIK syndrome [33,34,35] 
SNAP29 CEDNIK syndrome [33,34,35] 
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VPS33B Arthrogryposis-renal dysfunction-cholestasis syndrome [33,34,35] 
CDSN Epidermolysis bullosa simplex, hypotrichosis simplex, peeling skin syn-
drome 
[36] 
SPINK5 Netherton syndrome [37,38] 
ST14 Autosomal recessive congenital ichthyosis [37,38] 
CTSA Peeling skin syndrome [39,55] 
GJB2 Erythrokeratodermia variabilis, keratitis-ichthyosis-deafness syndrome, 
palmoplantar keratodermas, ectodermal dysplasias, deafness syndromes  
[40,41,42,43] 
GJB3 Erythrokeratodermia variabilis, deafness syndromes [40,41,42,43] 
GJB4 Erythrokeratodermia variabilis [40,41,42,43] 
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CLDN1 Neonatal sclerosing cholangitis with ichthyosis syndrome [40,41,42,43] 
 
Pharmacological Targeting of the Epidermal Barrier Current Pharmaceutical Design, 2016, Vol. 22, No. 00    3 
of the epidermal barrier significantly [14,15]. The precursor protein 
of filaggrin, profilaggrin, is encoded by the filaggrin (FLG) gene, 
which contains several tandem filaggrin repeats [16,17]. The segre-
gation of these repeats results in polymorphic variation in the size 
of the FLG gene due to simple allelic differences between individu-
als [16,17]. Another major component of the cornified cell envelope 
is the protein encoded by the loricrin (LOR) gene [18]. The corni-
fied envelope proteins are crosslinked with disulfide and gamma-
glutamyl-lysine isodipeptide bonds by transglutaminase enzymes 
such as the one encoded by the transglutaminase 1 (TGM1) gene 
[17]. Other clinically relevant genes contributing to the proper func-
tioning of corneocytes are the following: the proteasome matura-
tion protein (POMP) gene, encoding a protein pivotal in protea-
some assembly [19], the excision repair complementing defective in 
Chinese hamster (ERCC) 2 and 3 genes and the chromosome 7 
open reading frame 11 (C7ORF11) gene, encoding proteins impor-
tant in DNA transcription and excision repair [20,21].  
 Other genes contribute to epidermal barrier formation either 
through the metabolism of fatty acids, triglycerides and cholesterol 
or through lipid transport and secretion. Long-chain fatty aldehydes 
are oxidized to fatty acids by the enzyme encoded by the fatty alde-
hyde dehydrogenase (FALDH) gene [22]. Branched fatty acids are 
broken down by another enzyme encoded by the phytanoyl-CoA 
hydroxylase (PHYH) gene [23,24]. The 12R-lipoxygenase 
(ALOX12B) and the epidermis-type lipoxygenase (ALOXE3) genes 
encode enzymes catalyzing the conversion of arachidonic acid to 
12R-hydroxyeicosatetraenoic acid [25]. The proteins encoded by 
the cytochrome P450 family 4 subfamily f polypeptide 22 
(CYP4F22), the NIPA-like domain-containing 4 (NIPAL4) and the 
lipase family member N (LIPN) genes also participate in the signal-
ing pathways associated with fatty acids and triglycerides [26,27]. 
The enzymes encoded by the steroid sulfatase (STS), the emopamil-
binding protein (EBP) and the membrane-bound transcription fac-
tor protease site 2 (MBTPS2) genes are implicated in epidermal 
barrier dysfunction through the metabolism of cholesterol [28-30]. 
The solute carrier family 27 member 4 (SLC27A4) and the ATP-
binding cassette subfamily A member 12 (ABCA12) genes encode 
transporter proteins [31,32]. Proteins encoded by the adaptor-
related protein complex 1 sigma-1 subunit (AP1S1), the synaptoso-
mal-associated protein 29-kd (SNAP29) and the vacuolar protein 
sorting 33 B (VPS33B) genes are involved in trafficking [33-35].  
 In the development of the epidermal barrier, other genes are 
also implicated through coding either structural components of the 
cell–cell junctions or proteolytic enzymes regulating the digestion 
of these junctions. The protein encoded by the corneodesmosin 
(CDSN) gene participates in the formation of corneodesmosomes 
[36], while the proteins encoded by the serine protease inhibitor 
Kazal-type 5 (SPINK5) and the membrane-type serine protease 1 
(ST14) genes are involved in the degradation of these structures 
[37,38]. These proteolytic enzymes are regulated by inhibitors, such 
as the cysteine proteinase inhibitor encoded by the cystatin A 
(CTSA) gene [39]. Some of the genes involved in the development 
of other cell–cell junctions, such as the gap junction protein beta 
(GJB) 2, 3 and 4 genes and the claudin 1 (CLDN1) gene, also con-
tribute to the proper function of the epidermal barrier [40-43].  
 The above reviewed genes have clinical significance, since their 
mutations result in the development of rare, monogenic diseases. 
Many mutations result in genodermatoses, characterized by epi-
dermal barrier dysfunction due to abnormalities in corneocytes, 
epidermal lipids or cell–cell junctions. Disease-causing genetic 
variations of the genes implicated in the development of corneo-
cytes are associated with high clinical heterogeneity. TGM1 muta-
tions have been linked to several clinical variants of autosomal 
recessive congenital ichthyosis, such as the well known lamellar 
ichthyosis phenotype and the self-healing collodion baby pheno-
type, in which the condition is present at birth, but spontaneously 
improves [44,45]. A very rare form of this latter clinical variant is 
the acral self-healing collodion baby, in which the membrane is 
located on the extremities only [46]. TGM1 mutations can also lead 
to development of bathing suit ichthyosis, another clinical form of 
autosomal recessive congenital ichthyosis, in which scaling is pro-
nounced in the bathing suit area and is less pronounced on extremi-
ties [47]. FLG mutations have been associated with the develop-
ment of the most common and mildest form of hereditary non-
syndromic ichthyosis, ichthyosis vulgaris [17,48]. Of note, among 
common diseases, FLG variations are major predisposing factors 
for atopic dermatitis [49]. KRT1 mutations impairing the interaction 
and network formation of intermediate filaments are frequently 
associated with epidermolytic hyperkeratosis [50]. KRT1 mutations 
are also involved in the development of palmoplantar keratodermas 
[51]. KRT2 and KRT10 disease-causing genetic variations can also 
be associated with epidermolytic hyperkeratosis [52]. KRT10 muta-
tions can also contribute to ichthyosis with confetti, a rare form of 
ichthyosis with a reticulated pattern [53]. LOR mutations result in 
loricrin keratoderma [18]. POMP causative variants are associated 
with keratosis linearis with ichthyosis congenita and sclerosing 
keratoderma [19]. ERCC2, ERCC3 and C7ORF11 mutations are 
pivotal in trichothiodystrophy; additionally, ERCC2 and ERCC3 
causative variants are implicated in xeroderma pigmentosum 
[20,21].  
 Causative variations of the genes linked with abnormal lipid 
metabolism and transport and, thus consequently epidermal barrier 
dysfunction, can contribute to the development of clinical variants 
of the same disease with overlapping symptoms, since ALOX12B, 
ALOXE3, CYP4F22, NIPAL4, ABCA12 and LIPN mutations are 
frequently associated with the different clinical forms of autosomal 
recessive congenital ichthyosis [23,25-27,32]. FALDH mutations 
result in Sjögren-Larsson syndrome [22]. PHYH causative variants 
are associated with Refsum syndrome [24]. STS disease-causing 
variants contribute to the development of X-linked ichthyosis [28]. 
EBP mutations are linked with Conradi-Hünermann-Happle or 
MEND syndromes [29,54]. MBTPS2 mutations can lead to the de-
velopment of ichthyosis follicularis-alopecia-photophobia syn-
drome, keratosis follicularis spinulosa decalvans and Olmsted syn-
drome, characterized by mutilating palmoplantar keratoderma with 
periorificial keratotic plaques [30]. SLC27A4 mutations lead to 
ichthyosis prematurity syndrome [31].  
 Disease-causing variants of genes implicated in trafficking can 
lead to severe multisystem disorders with overlapping clinical fea-
tures: AP1S1 mutations cause the mental retardation, enteropathy, 
deafness, neuropathy, ichthyosis, and palmoplantar keratoderma 
(MEDNIK) disorder, whereas SNAP29 mutations are associated 
with cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar 
keratoderma (CEDNIK) [34,35]. VPS33B mutations contribute to 
development of arthrogryposis-renal dysfunction-cholestasis syn-
drome [33]. 
 Mutations of genes implicated in the formation and degradation 
of cell–cell junctions and, thus consequently epidermal barrier dys-
function, are associated with high clinical heterogeneity. CDSN 
mutations can lead to the development of epidermolysis bullosa 
simplex, hypotrichosis simplex and peeling skin syndrome [36]. 
CTSA mutations are also implicated in peeling skin syndrome [55]. 
SPINK5 causative variants are associated with Netherton syndrome 
and atopy [38]. ST14 disease-causing variants result in autosomal 
recessive congenital ichthyosis [37]. Since GJB2, 3 and 4 genes are 
expressed in a wide range of organs and tissues, their mutations are 
implicated in numerous diseases, such as erythrokeratodermia vari-
abilis, keratitis-ichthyosis-deafness syndrome, palmoplantar kerato-
dermas, ectodermal dysplasia and deafness syndromes [40,42,43]. 
CLDN1 mutations contribute to the development of neonatal scle-
rosing cholangitis associated with ichthyosis syndrome [39]. The 
functional classification of the diseases featuring epidermal barrier 
dysfunction gives insight into the functional relationships among 
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these entities and also highlights the significant clinical heterogene-
ity of these diseases.  
DEVELOPMENT OF THE EPIDERMAL BARRIER 
 All of the anatomic elements of the skin are fully developed by 
weeks 22 to 24 of gestation, whereas functional and biochemical 
maturity requires a much longer time. At gestational week 24, the 
epidermis is immature, with the SC consisting of only one to two 
cell layers [56,57]. In preterm infants, the full thickness of the skin 
(0.9 mm) is much less than in term infants (1.2 mm), and this is also 
the case for the thickness of the epidermis and SC [56,57]. The 
uppermost layer of the epidermis, the SC, which consists of corneo-
cytes, plays a considerable role in the barrier function of the skin 
[58-60]. The physical barrier of the skin represented by the SC is 
mainly determined by its thickness and integrity. By weeks 33 to 34 
of gestation, the SC has attained structural and functional maturity, 
although the active adaptation and maturation processes continue 
after birth [56,57,59,60]. Changes in skin pH, development of the 
protecting acid envelope and continuous colonization by cutaneous 
microbiota play a crucial role in the adaptation process [56-59]. 
 The basic structural differences between the skin of a preterm 
neonate, a term neonate and an adult are of considerable importance 
in clinical practice. The structure of the skin of a full-term neonate 
is similar to that of an adult, but it is much thinner and more vulner-
able [60,61]. The skin of a term neonate is structurally and func-
tionally more ready to adapt to an air environment than the skin of a 
premature infant, which is in homeostasis with a fluid environment. 
After delivery, premature skin matures rapidly over 2 to 8 weeks, 
but this process takes significantly longer for extremely premature 
neonates [56,57,60]. 
 In premature infants, the structural and functional maturation of 
the epidermis accelerates significantly, taking approximately 2 
weeks after birth. As a consequence of this accelerated maturation 
period, the epidermis of an extremely premature infant undergoes a 
dramatic development during these 2 weeks, resulting in markedly 
decreased transepidermal water loss (TEWL) and a reduced possi-
bility to absorb various toxic agents [58,60]. Preterm neonates are 
obviously highly vulnerable during this 2-week period. Septic com-
plications occur mainly in the first few days or the first 2 weeks of 
life and are the most common cause of mortality in this special 
population. The compromised epidermal barrier function results in 
an enhanced susceptibility to severe invasive infections, high rates 
of TEWL, thermal instability, electrolyte imbalance, increased per-
cutaneous absorption of chemicals and drugs, and easily induced 
skin traumas; these clinical complications are relevant determinants 
of the high morbidity and mortality rates for preterm infants [56-
58,61]. In extremely premature infants, the TEWL can be as much 
as 10–15 times higher than in full-term infants; a neonate born at 24 
weeks of gestation can lose 13% body weight on the first day of life 
as a consequence of the high fluid loss due to the virtual absence of 
the epidermal barrier [57,58,60]. TEWL is influenced by the gesta-
tional age of the infant, body region, and humidity of the environ-
ment. TEWL and percutaneous absorption are inversely propor-
tional to gestational age, and SC hydration increases with age 
[56,57,60]. 
 Another anatomical-structural difference between premature 
and mature infants is that the dermoepidermal junction is flat and 
anchoring fibrils, anchoring filaments and hemidesmosomes are 
fewer and smaller in preterm neonates, which results in a decreased 
resistance to shear forces. Due to the immaturity of the dermoepi-
dermal junction, the epidermis and dermis can easily separate from 
each other; moreover, bullae can develop much more easily after 
thermal or mechanical impact. The skin is therefore fragile and 
prone to inadvertent cutaneous injury [56,57,61]. The dermis is also 
thinner, less collagenized and more gelatinous, and this gives rise to 
an increased risk of oedema, resulting in the risk of ischaemic in-
jury. Moreover, in consequence of the thin layer of subcutaneous 
fat and immature eccrine glands, premature infants have a compro-
mised thermoregulatory capability [56,57]. 
IMPAIRED EPIDERMAL BARRIER IN INFLAMMATORY 
SKIN DISEASES 
 Defective epidermal barrier function is the main feature of the 
most common inflammatory skin disorders, such as atopic dermati-
tis and, to a lesser extent, psoriasis [62,63]. Atopic dermatitis is a 
chronic skin disease affecting up to 20% of the pediatric population 
in developed countries. The main pathogenetic factor of atopic 
dermatitis is skin barrier damage, where the crucial predisposing 
factors are mutations and intragenic variations in the copy number 
of FLG monomers [49,64]. However, recent data suggest that the 
inflammatory cytokines and chemokine milieu in atopic skin can 
also down-regulate FLG gene expression, resulting in filaggrin 
deficiency and impaired epidermal barrier. These data suggest that 
severe skin inflammation and filaggrin mutations similarly alter the 
skin barrier [65,66]. As inherited or acquired barrier defect is the 
major pathogenic factor of the disease, restoration of the impaired 
barrier is the key therapeutic approach in the treatment of atopic 
dermatitis (Fig. 1).  
 Psoriasis is also a multifactorial inflammatory skin disease, 
affecting approximately 2–3% of the population. Genetic and envi-
ronmental factors result in impaired skin barrier in psoriatic lesions, 
and this danger signal might contribute to the hyperproliferation 
and inflammatory cytokine production of keratinocytes [63]. As 
damage to the skin barrier results in further inflammatory cytokine 
production, barrier restoring therapy is an important strategy in the 
management of chronic inflammatory skin diseases. 
BARRIER RESTORING THERAPIES 
Moisturizers 
 Xerosis, or dry skin, is frequently the most apparent sign indi-
cating impairment of the skin’s barrier function. Dry skin can be 
caused by altered environmental factors (e.g., seasons, climate, 
excessive bathing, etc.) or endogenous factors (e.g., aging, defi-
ciencies in the skin’s natural moisturizing factor (NMF), barrier 
lipid content, etc.) [67-69]. Moisturizers are widely applied to treat 
dry skin caused by different factors and are based on several formu-
lations which contribute to barrier repair, reduction of TEWL or 
aesthetic improvement of irritated skin [67]. Moisturizers, which 
can be prescription but are more often over-the-counter formula-
tions, belong to the standard therapy of atopic dermatitis [70] and 
may also be useful in the treatment of irritant contact dermatitis. 
Three main classes of moisturizers can be distinguished: emollients, 
occlusives and humectants (Table 2).  
 Emollients are oily substances which are designed to bring 
small lipid droplets into the cracks between desquamating corneo-
cytes in dry skin, thereby increasing the softness, flexibility and 
smoothness of the skin [71]. Containing oils and lipids (e.g., differ-
ent fatty acids from palm oil, coconut oil and wool fat) [72], emol-
lients are designed to maintain healthy skin conditions rather than 
to repair damaged skin or have long-term effects [67]. 
 Occlusives are also lipophilic preparations which provide a 
hydrophobic barrier on the skin surface to reduce TEWL. Moreo-
ver, this film protects from external irritants. Thus, these prepara-
tions are applied to dry or damaged skin because they promote bar-
rier repair due to the mentioned mechanisms. Petrolatum is one of 
the most effective occlusives. Lanolin, mineral oil, beeswax, soy-
bean oil, paraffin and propylene glycol are also used as occlusives. 
Silicones (e.g., dimethicone, cyclomethicone) are relatively new 
hypoallergenic occlusives. A disadvantage of occlusive prepara-
tions is that they can be aesthetically less pleasing than oil-in-water 
emulsions [67,68,71]. 
 Humectant-based moisturizers are frequently used to treat dry 
skin. These preparations, which contain inter alia polyols (e.g., 
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glycerol, sorbitol and mannitol), provide hydrating effects to the 
skin by attracting and binding water from the deep epidermis and 
the environment. Compared to other formulations, they are ab-
sorbed faster and therefore are aesthetically better, promoting pa-
tient compliance [67,73]. Polyols may provide protection against 
irritation via different pathways. Certain advantageous effects of 
polyols originate in their chemical structure. It is known that glyc-
erol, which is the most frequent polyol in dermatological topical 
preparations, diffuses into the SC and retains water in the skin. 
Further, glycerol may interact with SC lipid structures and proteins, 
altering their water-binding and/or hydrophilic properties [74]. The 
hydrating effect of glycerol has been shown in a number of animal 
experiments and human studies [75]. Furthermore, glycerol pro-
motes skin barrier function [76,77]. This effect may be explained 
by the moisturizing property of glycerol, since an inverse relation-
ship between TEWL and SC hydration is known [1]. Moreover, 
glycerol reduces the density and the average radius of aqueous 
pores in SC, hereby decreasing the ability of irritant agents to pene-
trate the SC [78]. In addition to moisturizing and providing barrier 
restoring potential, glycerol improves mechanical properties of the 
skin [79]). There is a correlation between SC hydration and skin 
mechanical properties [80]. The skin friction coefficient also shows 
positive correlation with SC hydration [81]. Another study suggests 
that the effects of glycerol on mechanical parameters may be inde-
pendent of its hydrating ability [79]. Effects of glycerol have been 
extensively studied; however less information is available for other 
polyols. Previously, we found that xylitol also suppresses skin irri-
tation [65]. Mannitol alone had no effect on skin irritation [65], but 
combined application of mannitol and hyaluronic acid increased 
skin hydration and elasticity [82]. In contrast, sorbitol was found to 
improve barrier function and act as a moisturizer [83]. 
 In addition to inducing physical or chemical alterations, polyols 
might also change gene expression. In vitro experiments have 
shown that glycerol decreases the expression of human leukocyte 
antigen DR (HLA-DR), thereby reducing inflammation, whereas 
xylitol increases the expression of filaggrin [84]. Filaggrin, as a 
source of NMF and in other ways, contributes to hydration and 
homeostasis of the skin [85]. Recent animal experiments have re-
vealed that both glycerol and xylitol decrease the expression of 
tumor necrosis factor alpha (TNF-α) and interleukin 1-beta (IL-1ß) 
in sodium lauryl sulphate (SLS) induced acute irritation [86]. In this 
experimental setup, application of polyols inhibited the SLS-
induced elevation of TEWL, moderated the irritant-induced in-
crease in dermal blood flow and prevented accumulation of lym-
phocytes and neutrophil granulocytes. Further, it was found that 
both glycerol and xylitol hamper the penetration of irritant agents 
[86]. Thus, polyols exert anti-irritant effects via different pathways.  
 Other important factors are the antimicrobial effects of polyols. 
Barrier damage leads to changes in skin flora [87]; therefore, pa-
tients with irritant or atopic dermatitis may need protection against 
bacterial colonization. Glycerol in 85% concentration was found to 
have antimicrobial effects [88]. Additionally, glycerol possesses 
virucidal properties [89]. However, Gram-positive species are less 
susceptible to glycerol than Gram-negatives. Xylitol, combined 
with farnesol [90] or with glycerol [91] effectively eliminates 
Gram-positive bacteria, and its effective concentration was found to 
be 5% in both studies. Hence, application of polyols may prevent 
both irritation and bacterial colonization of the skin (Fig. 2).  
 
 
 
 
 
 
 
 
 
 
Fig. (1). The pathogenesis of atopic dermatitis. The interaction of genetic, environmental and immunologic factors create a permissive environment for the 
initiation and progression of the disease. Through the impared epidermal barrier penetration of external allergens, microbes and microbial compounds are 
enhanced, creating immune activation and subsequent inflammation. 
 
Table 2. Main classes of moisturizers. 
Type Characteristics Examples 
Emollients Smoothing and softening skin Oils, lipids (e.g., stearic, linoleic, linolenic, oleic, lauryl acids) 
Occlusives Providing hydrophobic barrier which protects from 
loss of water and external irritants 
Petrolatum, lanolin, mineral oil, beeswax, propylene glycol, 
silicones, etc. 
Humectants Attracting and binding water in SC Glycerol, sorbitol, urea, lactic acid, amino acids, etc.  
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 A new generation of moisturizers could contain special ingredi-
ents which supply normal skin components. Ceramides, with cho-
lesterol and fatty acids, belong to the main lipid groups of SC and 
play a pivotal role in barrier function [92]. NMF, originating from 
the catabolism of filaggrin, maintains adequate SC hydration [85]. 
NMF is a mixture of free amino acids, inorganic salts, sugars, lactic 
acid and urea. It should be noted that that a combination of different 
types of moisturizers can be advantageous. Humectants can be 
combined with occlusive components when applied to skin with a 
defective barrier to attract water and to prevent its evaporation [93]. 
Ceramides, pseudoceramides and NMFs have been studied and 
added to commercial moisturizers to hydrate skin and improve bar-
rier function [94]. 
Anti-Inflammatory Therapies 
 Inflammation in the skin results in epidermal barrier damage 
similar to that present in patients with filaggrin mutation, suggest-
ing that anti-inflammatory treatment might affect the barrier func-
tions of the skin. 
Topical Glucocorticosteroids  
 Topical corticosteroids (TCS) have been widely used for the 
treatment of inflammatory skin disorders in dermatological practice 
for decades. Corticosteroids have numerous anti-inflammatory, 
antiproliferative and immunosuppressive effects, and topical medi-
cations are available in different formulations with a wide range of 
potency. TCS remain the mainstay and gold standard for the treat-
ment of acute inflammatory symptoms in AD and can achieve ex-
cellent results in both short-term and proactive maintenance therapy 
[57,95-98]. Topical steroids result in rapid improvement of skin 
inflammation and pruritus, but have opposing effects on barrier 
functions [95,99,100]. Positive effects of topical corticosteroids on 
the skin barrier include the increase of SC hydration, decrease of 
TEWL, and normalization of filaggrin and loricrin expression 
[95,100,101]. However, human studies and animal models demon-
strated that long-term application of local glucocorticoids resulted 
in significant impairment of epidermal barrier function and homeo-
stasis. Morphological, physicochemical and functional alterations 
include decreased epidermal proliferation and differentiation, inhi-
bition of the synthesis of epidermal barrier lipids and antimicrobial 
peptide formation, decrease of lamellar body formation, delay of 
barrier recovery, and reduction of the integrity and cohesion of SC; 
additionally, topical steroids also have negative effects on epider-
mal immune cells [95,99,100]. The application of topical steroids in 
special, advanced vehicle formulations and adequate adjunctive 
barrier repair therapy with emollients and moisturizers can signifi-
cantly reduce these negative effects and promote the maintenance 
of epidermal barrier functions [95,99]. There are also several well 
known cutaneous side-effects of prolonged use of topical glucocor-
ticosteroids, such as atrophy, striae, purpura, telangiectasias, hyper-
trichosis, alopecia, hyperpigmentation and impairment of wound 
healing; these effects are mostly preventable with rational applica-
tion of the medications [57,95,102].  
Topical Calcineurin Inhibitors 
 The introduction of topical calcineurin inhibitors (tacrolimus 
and pimecrolimus) resulted in a significant breakthrough in the anti-
inflammatory treatment of atopic dermatitis. These macrolactam 
derivatives have more specific immunomodulatory and anti-
inflammatory effects than glucocorticoids, acting by inhibition of 
proinflammatory cytokine expression in T-lymphocytes and other 
inflammatory cells. In contrast to topical steroids, pimecrolimus 
and tacrolimus do not induce skin atrophy, and thus calcineurin 
inhibitors are suitable for long-term maintenance therapy even on 
the head, neck and intertriginous areas [96-98]. Topical calcineurin 
inhibitors influence the epidermal barrier function in several ways, 
and a beneficial effect is observed by improving SC hydration and 
reducing TEWL [100,103]. However, local calcineurin inhibitors 
might also have negative impacts on epidermal barrier function by 
decreasing epidermal lipid synthesis, lamellar body secretion and 
antimicrobial peptide expression and production. The calcineurin 
inhibitor-induced impairment of the permeability and antimicrobial 
barrier could be prevented by emollient treatment [103]. 
TRANSDERMAL DRUG DELIVERY 
 Barrier function provided by the SC is indispensable to avoid 
the loss of water and to provide protection against irritant and 
causative agents. However, the same barrier often hampers trans-
dermal drug delivery. This method is a useful alternative pathway 
for therapeutic agents that are prone to decompose in the gastroin-
testinal tract and permits the achievement of relatively high local 
drug concentrations without systemic side effects. Due to the epi-
dermal barrier, different techniques are required for the enhance-
ment of skin permeability. Methods modifying the barrier proper-
ties can be passive or active. Passive methods include the influenc-
ing of drug and vehicle interactions and optimization of formulation 
to modify SC structure [104]. A widely used passive method is the 
application of chemical penetration enhancers that facilitate drug 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Effects of polyols on the skin. 
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permeation across the skin. Several compounds are able to contrib-
ute to a better penetration, e.g., alcohols, amides, esters, ether alco-
hols, fatty acids, glycols, pyrrolidones, sulfoxides, surfactants and 
terpenes [105]. Penetration enhancers have different mechanisms of 
action, e.g., increasing the fluidity of the SC lipid bilayers, interac-
tion with intercellular proteins, disruption or extraction of intercel-
lular lipids, increasing the drug’s thermodynamic activity or in-
creasing SC hydration [106,107]. Their primary disadvantage is that 
chemical penetration enhancers often evoke skin irritation (local 
inflammation) and their efficacy is relatively low [108-110].  
 Another passive method is the use of special carrier systems to 
increase drug flux into and through the skin. These carrier systems 
can be nanoparticles and nanofibers which can be used to enhance 
solubility of highly hydrophobic drugs, provide controlled and sus-
tained release of drugs, increase the stability of therapeutic agents, 
and deliver higher drug concentrations to target areas. Several types 
of nanoparticles are available: natural polymeric (e.g., chitosan and 
albumin), synthetic polymeric (e.g., tyrosine-derived polymeric 
nanospheres, poly(lactic-co-glycolic acid)), lipid-based (liposomes, 
solid-lipid), metallic and silica, as well as dendrimers. However, 
only a few of these techniques have been translated into clinically 
used products so far. Hence, further clinical studies are needed 
[111]. Furthermore, prodrugs can also be used. Prodrugs are syn-
thesized by a chemical modification of a drug for more optimal 
physicochemical and/or pharmacokinetic properties. After delivery, 
the prodrug is cleaved by enzymes leading to the formation of the 
parent drug [112]. Hyaluronic acid is an effective moisturizer, but 
its penetration ability is poor. However, cross-linking the molecule 
results in better penetration through human epidermis and living 
animal skin [113].  
 Active, physical methods involve several different techniques 
(e.g., use of electrical forces, lasers, ultrasound and microneedles). 
Electrical force can be used as iontophoresis or electroporation. The 
latter is a promising method which temporarily creates aqueous 
pores in cell membranes using electric pulses of high voltage and 
short duration. Electroporation successfully enhances skin perme-
ability for molecules with different lipophilicities and sizes, includ-
ing high-molecular-weight biopharmaceuticals. Nevertheless, the 
relationship between electroporation and skin irritation should be 
clarified. Since high voltage pulses are used, it is important to en-
sure that there are no harmful effects in the skin [114].  
 Lasers can also be used to assist drug delivery. By means of 
laser, fractional photothermolysis can be performed: i.e., multiple 
vertical columns of tissue in the SC and underlying layer are ther-
mally destroyed to create unimpeded channels. On treated skin, the 
channels and the surrounding thermally coagulated tissue enhance 
penetration while the untreated area serves as a reservoir for regen-
eration [115].  
 Ultrasound is able to affect skin permeability. Penetration of 
cationic, neutral and anionic particles and also those of gold 
nanoparticles and dendrimers are enabled by ultrasound [116].  
 Microneedle devices are composed of arrays of micron-size 
needles. When applied to the skin surface, they bypass the SC with-
out stimulating dermal nerves. The holes created by the needles can 
be used to deliver drugs on the skin surface to the dermal microcir-
culation [117]. These techniques may also be combined to increase 
efficacy and to reduce side effects. 
THE EPIDERMAL BARRIER: FUTURE PERSPECTIVES 
 Understanding the molecular mechanism of epidermal barrier 
function and the inherited factors leading to genetic diseases result-
ing in skin barrier defects might pave the way for better treatments 
not only for rare hereditary, but also for common multifactorial 
inflammatory skin diseases. Because of the importance of the intact 
barrier for the healthy state of our bodies, maintenance and restora-
tion when it becomes compromised is vital.  
 Transdermal drug delivery represents an attractive opportunity 
for the administration of different drugs. Scientific and technologi-
cal advances by targeted disruption of the epidermal barrier result-
ing in better transdermal penetration of various treatments will have 
a widespread impact in medicine. 
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